Victory Capital Management Inc. Buys 1,094,759 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Victory Capital Management Inc. increased its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 56.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,023,474 shares of the company's stock after buying an additional 1,094,759 shares during the quarter. Victory Capital Management Inc. owned 0.27% of Teva Pharmaceutical Industries worth $66,637,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Smithfield Trust Co increased its position in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock worth $50,000 after purchasing an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries in the fourth quarter worth approximately $66,000. Venturi Wealth Management LLC bought a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $60,000. Finally, IFP Advisors Inc lifted its stake in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after acquiring an additional 1,960 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TEVA has been the topic of several analyst reports. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Bank of America lowered their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Friday. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Finally, Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Remove Ads

Insider Activity

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Trading Up 10.0 %

Shares of TEVA stock traded up $1.47 during trading hours on Tuesday, reaching $16.14. The company had a trading volume of 19,722,844 shares, compared to its average volume of 12,955,174. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The company has a 50 day moving average of $18.70 and a 200 day moving average of $18.35. The firm has a market cap of $18.29 billion, a price-to-earnings ratio of -11.13, a P/E/G ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.